Skip to main content

Deal Alert: Vyome Biosciences Raises Series A Financing

From the Press Release: 

Vyome Biosciences Private Limited, an innovation driven dermatology company focused on developing novel and innovative treatments for common skin conditions such as dandruff, acne, pigmentation disorders and wound healing, today announced that it has closed Series A financing round of Rs. 18.50 crore. The round was led by IndoUS Venture Partners (IUVP), with Aarin Capital and Navam Capital as coinvestors. 

Vyome will deploy the new financing to advance the clinical development of its lead antidandruff products, and to accelerate the pre-clinical development of its anti-acne products. These safer and more effective next-generation treatments are being developed by harnessing emerging genetic information on the disease-causing microbes with advances in nanotechnology. Vyome has already filed multiple Indian and Global patents on these technologies. “Our vision is to emerge as a company that launches global products from India and competes with the best in the world” said Dr Shiladitya Sengupta, Co-Founder of Vyome and Assistant Professor of Medicine at Harvard Medical School.

“Vyome is developing creative approaches that will transform how skin diseases will be treated in the future. Dermatology is one area that has not seen much innovation for over five decades but with the recent advances in science, significantly more effective solutions become possible. Vyome has attracted top talent globally, and the ability to generate multiple highly differentiated products by harnessing cutting-edge scientific platforms creates a very compelling value proposition” said Dr R.A. Mashelkar, Chairman of Vyome's Board of Directors and former Director General of CSIR.

“We are backing a top notch scientific team assembled in India that is leveraging leadingedge platform technology to develop promising products to address the $20 billion global dermatology market” said Dr Kumar Shiralagi, Managing Director, IUVP. 

“Nanotechnology applications are poised to completely transform the future of pharmacotherapy and consumer products as did biotechnology beginning in the 1980s. We are pleased to support some of the leading academic scientists and ventures in this area” said Dr Ranjan Pai, Managing Partner, Aarin Capital. 

“Navam is delighted to welcome IUVP and Aarin as investors in Vyome. The work Vyome is doing will challenge assumptions and change perceptions about India’s capacity to deliver genuine innovation. We are demonstrating what Indian technology companies can achieve if they focus on building innovative products,” said Rajeev Mantri, Co-Founder and President of Vyome, and Executive Director of Navam Capital. 

About Vyome Biosciences Private Limited 

Vyome is a privately-held biopharmaceutical company based in Delhi focused on the development of novel therapeutics for dermatology applications. The Company, which had raised seed funding from Navam Capital, was founded in August 2010 by Dr Rajesh Gokhale, Director of Institute of Genomics & Integrative Biology in Delhi, Dr Shiladitya Sengupta, Co- Chair at the Center for Regenerative Therapeutics at Brigham & Women’s Hospital in Boston, USA and Assistant Professor of Medicine at Harvard Medical School, and Rajeev Mantri, Executive Director of Navam Capital.

Vyome has assembled a world-class management and scientific team, alongside a Board of Directors and Scientific Advisory Board that collectively have a significant track record of conducting acclaimed scientific research, developing breakthrough products and building sustainable businesses. 

About IUVP 

IndoUS Venture Partners (IUVP) is a leading venture capital firm which provides early and mid- stage funding to new or growing businesses in India. Our team comprises experienced entrepreneurs and executives who understand the model of incubating ideas and transforming them into successful enterprises. It is our privilege to fund entrepreneurial ideas and offer collaborative partnerships. We invest in tomorrow's business leaders, explosive new markets and enterprises that will transform our future. We foster close partnerships with our portfolio companies, and build strong relationships based on integrity, trust and mutual respect. At IUVP, we are committed to redefining Indian entrepreneurship and are excited about India's potential to be an innovative player in the global market. Our approach to investing and our philosophy of building successful companies makes us the ideal partner for entrepreneurs. 

About Navam Capital

Navam Capital is a venture capital firm focused on seed and early-stage investments in energy, life sciences, Internet, advanced materials and other emerging technology sectors. Navam backs innovation-driven companies that are developing significantly differentiated products in the pursuit of large market opportunities. Navam was the founding investor in Vyome Biosciences, investing Rs 4.50 crore in 2010. 

About Aarin Capital 

Aarin Capital invests in innovative ideas in the health care, life sciences and technology based products and services business pursuing large market opportunities that are led by driven and committed teams.

Popular posts from this blog

PE-VC investments in Q2'23 decline 33% to $9.9 Billion

Private Equity-Venture Capital (PE-VC) investments in India during the quarter ended June 2023 (Q2'23), at $9.85 Billion across 182 deals, registered a 33% decrease compared to the same period in 2022 (which saw $14.6 Billion being invested across 371 deals). The investment amount however rose 74% compared to the immediate previous quarter (which saw $5.7 Billion being invested across 181 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. The PE-VC investment figures for the first 6 months of 2023 - at $15.5 Billion (across 363 deals) - was 50% lower compared to the same period in 2022 (which saw $31 Billion being invested across 800 deals). Q2’23 witnessed 19 mega deals ($100 M+

Chiratae, Speciale and Stride Ventures win APEX'24 Venture Capital Awards

Chiratae Ventures, Speciale Invest and Stride Ventures were awarded as among the leading Venture Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) VC Investor of the Year Chiratae Ventures received the Venture Capital Investor of the Year 2023 Award on the back of 10 part exits totaling $178 million via Secondary Sales during the year. Its exits included those from retail unicorn Lenskart, SaaS Startup Pixis and baby pr

Blackstone, MO Alts and InvAscent win APEX'24 Private Equity Awards

Press Release Blackstone, MO Alternates (formerly Motilal Oswal PE) and InvAscent were awarded as among the leading Private Equity and Growth Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) PE Investor of the Year Blackstone received the Private Equity Investor of the Year 2023 Award on the back of strong complete exits during the year: from Sona Comstar and IBS Software. Ganesh Mani and Amit Dalmia, Senior Managing D

Avendus tops League Table for Transaction Advisors to PE deals in Q1'23

Aeka Advisors and Ambit claim the No.2 & 3 slot Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for Q1 2023 advising 5 deals worth $808 million. Aeka Advisors stood second having advised 3 deals worth $228 million. Ambit followed with 4 deals worth $160 million. Ernst & Young ($114 million across 4 deals) and o3 Capital ($80 million across 2 deals) completed the top five for Q1 2023. Avendus acted as advisor to ADIA’s $500 million investment in omnichannel eyewear retailer Lenskart . Aeka Advisors acted as advisor to Kreditbee’s $160 million fundraise from Advent International, Mitsubishi UFJ Financial Group (MUFG) and existing investors. Ambit advised the $104 million fundraise of Freshtohome from Mount Judi Ventures, Iron Pillar, Amazon and others. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE

PE-VC investments fall 38% in 2023 to below $30 B

The value of investments by Private Equity - Venture Capital (PE-VC) firms in India fell by 38% to less than $30 Billion in 2023. PE-VC firms invested $29.7 Billion (across 756 deals) in Indian companies in 2023, compared to $47.6 Billion (across 1,362 deals) in the previous year, reports Venture Intelligenc e, a research service focused on private company financials, transactions, and their valuations. (Note: These figures exclude PE investments in Real Estate).                                                                                                                                                                      2023 witnessed 67 mega deals ($100 M+ rounds) worth $21.2 Billion, compared to 112 such investments worth $31.8 Billion in 2022. The $2.4 Billion investment in Manipal Hospitals by Temasek (which gained majority control) and TPG Capital was the largest PE-VC investment in 2023. This was followed by the $1.35 Billion buyout of education loans focused HDFC Credila